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hospital and primary care clinic in Korea
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Department of Urology, The Catholic University of Korea College of Medicine, Seoul, Korea
Purpose: The National Institutes of Health classification of prostatitis reported the proportion of chronic bacterial prostatitis, especially 
category II, at 3% to 10%. Because of the polymerase chain reaction (PCR) diagnosis technique, chronic prostatitis syndrome (CPS) 
with a known bacterial origin has increased recently. In this study, we evaluated the proportion of chronic bacterial prostatitis in a 
general hospital and a primary care clinic (PCC) in addition to the distribution of the microorganism in chronic bacterial prostatitis in 
Korea.
Methods: Two hundred and ninety-three patients were enrolled in this study. One hundred and five patients in the general hospital 
and 188 patients in the PCC were enrolled in the study. Using a questionnaire, all patients were checked for symptoms of urinalysis, 
expressed prostate secretion (EPS), EPS or V3 culture and PCR of EPS or VB3 for Chlamydia trachomatis, Ureaplasma urealyticum, 
Mycoplasma hominis, Mycoplasma genetalia, and Trichomatis vaginalis.
Results: In routine EPS or VB3 culture, 12 of 105 patients (11.4%) in the general hospital showed positive culture, but 77 of 188 patients 
(40.9%) in the PCC showed a positive culture. Escherichia coli, Streptococcus faecalis, Staphylococcus epidermidis, Staphylococcus 
hemolyticus, Staphylococcus aureus, and Pseudomonas were isolated in routine culture. In the PCR diagnosis, 37 of 105 patients (35.2%) 
in the general hospital were PCR positive, and 65 of 188 patients (34.5%) in the PCC were PCR positive. In the general hospital, C. 
trachomatis was the most common (49%), followed by U. urealyticum (24%), M. genetalia (16%), M. hominis (10%), and T. vaginalis (2%). 
In the PCC, U. urealyticum was the most common (45%), followed by C. trachomatis (34%), M. hominis (13%), M. genetalia (7%) and T. 
vaginalis (1%). The proportions of chronic bacterial prostatitis were 46.6% (49/105) and 67.5% (127/188) in the general hospital and 
PCC, respectively.
Conclusions: The total portion of chronic bacterial prostatitis was 59.3% (174/293). Culture-positive patients in the PCC were significantly 
higher than in the general hospital, but the number of PCR positive patients in the PCC was the same as in the general hospital.
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INTRODUCTION
Prostatitis is a disease diagnosed by clinical symptoms and 
signs evident in the microscopy of expressed prostatic secre-
tion (EPS), and in the culture of EPS and segmented samples, 
according to Meares and Stamey [1,2]. The generally accepted 
classification of prostatitis syndrome differentiates the follow-
ing: 1) acute bacterial prostatitis; 2) chronic bacterial prosta-
titis; 3) chronic pelvic pain syndrome (CPPS); inflammatory 
CPPS, white blood cells (WBCs) in semen (EPS)/voided blad-
der urine (VB3), noninflammatory CPPS, no WBCs in semen 
(EPSs)/VB3; 4) asymptomatic inflammatory prostatitis.
 Symptoms of prostatitis are vague and involve pain in the 
pelvic region, urethral symptoms, voiding dysfunction, sexual 




disorder, and possibly considerable psychosocial distress [3]. 
In addition to these clinical problems, the pathogenesis and 
etiology of prostatitis are only partially understood and re-
main controversial. Nickel et al. [4] reported that “prostatitis 
has a prevalence of 6% to 8%, is responsible for 25% of all male 
genitourinary clinic visits, and is the most common urological 
disorder in men aged under 50”. In a cross-sectional Finnish 
study, Mehik et al. [5] reported a 14% of lifetime prevalence in 
which 27% of Finnish men reported symptoms at least once 
per year, and 16% complained of persistent prostatitis symp-
toms.
 The disease entities in primary care clinics (PCCs) and 
tertiary centers are different. The causative pathogens and 
pathogen distributions might differ even in one disease en-
tity. Furthermore, disease entities differ between country and 
region. This difference is important because in epidemics, the 
treatment of causative organisms differs accordingly.
 The aim of this study was to investigate the etiology and the 
proportion of chronic bacterial prostatitis in a general hospi-
tal and a PCC in addition to the distribution of microorgan-
isms in chronic bacterial prostatitis in Korea.
MATERIALS AND METHODS
1. Patients
From November 2006 to August 2007, 105 patients in a gen-
eral hospital and 188 patients in a PCC, 293 patients were 
prospectively enrolled for evaluation. The inclusion criteria 
were as follows: 1) the disease duration was least 3 months; 2) 
antibiotic treatment for the same prostatitis symptoms within 
the last 3 months; 3) a bacterial count of 103 CFU/mL or more 
(only if gram-positive cocci are found in EPS; a bacterial count 
of 104 CFU/mL or more is required), and 10 or more WBC per 
high-power field in EPS or VB3; 4) 10 times as many bacteria 
in EPS and urine bladder samples collected immediately after 
prostate massage than in samples of first voided urine or mid-
stream urine. Nonbacterial prostatitis patients were excluded 
during the evaluation protocol. The purpose and method were 
explained to the patients before enrollment. All subjects that 
decided to participate in this study provided written informed 
consent. 
2. Methods
The following data were obtained for each patient: clinical 
history, symptom questionnaire, clinical status of digital rec-
tal examination, urinalysis, urethral swap specimens, EPS, EPS 
or VB3 culture according to the four-glass localization tech-
nique, and PCR of EPS or VB3.
 The Korean version of National Institutes of Health Chronic 
Prostatitis Symptom Index (NIH-CPSI) questionnaire was 
used for subjective assessment of the patients’ symptoms. 
 Urethral swab samples were analyzed for the microbio-
logical evaluation of Chlamydia trachomatis, Ureaplasma 
urealyticum, Mycoplasma hominis, Mycoplasma genitalia, 
and Trichomonas vaginalis. We used 1 mL specimens to de-
termine the number of WBCs and gram-positive and gram-
negative organisms. EPS and urine samples were examined 
for the presence of C. trachomatis, U. urealyticum, M. homi-
nis, M. genitalia, and T. vaginalis immediately after prostatic 
massage.
 We used complementary approaches to the polymerase 
chain reaction (PCR) technique. First, we developed specific 
PCR assays for each pathogen previously implicated, and then 
validated these assays for prostate tissue specimens. These 
specific PCR probes were directed at C. trachomatis, U. urea-
lyticum, M. hominis, M. genitalia, and T. vaginalis probes. Sec-
ond, we used broad-spectrum PCR assays to identify bacterial 
DNA sequences. Primer/probes were directed at two targets: 
common tetracycline resistant genes and bacterial ribosomal 
encoding genes. Tetracycline resistant genes are common in 
urogenital bacteria. Bacterial ribosomal encoding genes are 
distinct from mammalian ribosomal genes, so they are easily 
distinguished from human DNA. The 475 base pair products 
were then cloned in an attenuated strain of E. coli K12 and 
sequenced. Homology searches were performed to compare 
the identified sequences with the available existing data.
 For the PCR, the inclusion criteria for chronic prostatitis 
caused by Chlamydia trachomatis was the presence of C. 
trachomatis in EPS or VB3, absence of C. trachomatis in ure-
thral swabs and the absence of other possible pathogens of 
chronic prostatitis in EPS or VB3. The inclusion criteria for 
chronic prostatitis caused by Ureaplasma urealyticum and 
Mycoplasma hominis were the presence of U. urealyticum, 
M. hominis in EPS or VB3, absence of U. urealyticum or M. 
hominis in urethral swabs and the absence of other possible 
pathogens of chronic prostatitis in EPS or VB3. The inclusion 
criteria for M. genitalia and T. vaginalis were the same as those 
of described above. The criteria for noninflammatory chronic 
prostatitis and CPPS were the presence of clinical symptoms 
of prostatitis and the absence of white cells in EPS or VB3.
3. Statistical analysis
The Fisher exact chi-square test was used to assess statistical 
significance; P < 0.05 was considered significant. Two-sided 
tests of significance were performed for all analyses. Statistical 
analyses were performed using IBM SPSS ver. 18.0 (IBM Co., 







The mean ages of the patients were 45.4 ± 12.7 and 43.8 ± 11.3 
in the PCC and general hospital, respectively (P= 0.592) The 
mean treatment period for chronic bacterial prostatitis was 
13.4 ± 5.2 weeks 11.8 ± 4.4 weeks in the PCC and general hos-
pital, respectively (P = 0.274). For the responses to the NIH-
CPSI questionnaire, the mean pain scores were 9.6 ± 5.2 and 
9.4 ± 5.0. in the PCC and in general hospital, respectively (P=  
0.574). The mean voiding symptom scores were 4.7 ±3.1 and 
4.6±3.0 in PCC and the general hospital, respectively (P=0.291). 
The mean scores for quality of life were 7.2 ± 2.5 and 7.2 ± 3.1 
in the PCC and general hospital, respectively (P= 0.591) The 
total NIH-CPSI scores in the PCC and the tertiary general 
hospital were 21.0 ± 5.5 and 21.5 ± 7.4, respectively (P = 0.557) 
(Table 1).
2. Microbiological analysis with EPS culture analysis
In routine EPS or VB3 culture, 12 of 105 patients (11.4%) in 
the general hospital were culture positive. However, 77 of 
188 patients (40.9%) in the PCC were culture positive (Table 
2). The microorganisms obtained from culture were E. coli, S. 
faecalis, S. epidermidis, S. hemolyticus, S. aureus, and Pseudo-
monas species. The most common pathogen in the PCC was 
E. faecalis (19%), followed by Streptococcus agalactiae (17%), 
S. epidermidis (16%), and S. hemolyticus (8%), S. aureus (8%), 
Pseudomonas (8%) (Fig. 1). The analysis of the data from the 
general hospital found that the most common pathogen was 
E. coli (41%), followed by E. faecalis (20%), S. epidermidis 
(13%), and S. hemolyticus (13%) (Fig. 2).
3. Microbiological analysis with PCR analysis
The PCR analysis showed that 37 of 105 patients (35.2%) in 
the general hospital were PCR positive, and 65 of 188 patients 
(34.5%) in the PCC were PCR positive (Table 2). In the gen-
eral hospital, C. trachomatis was the most common pathogen 
(49%), followed by U. urealyticum (24%), M. genitalia (16%), 
M. hominis (10%), and T. vaginalis (2%) (Fig. 2). However, in 
the PCC, U. urealyticum is the most common pathogen (45%), 
followed by C. trachomatis (34%), M. hominis (13%), M. geni-
Table 1. Patient demographics 
Variable Primary care clinic General hospital P-value
Age (yr) 45.4±12.7 43.8±11.3 0.592
Treatment period (wk) 13.4±5.2 11.8±4.4 0.274
NIH-CPSI questionnaire
Pain score 9.6±5.2 9.4±5.0 0.574
Voiding score 4.7±3.1 4.6±3.0 0.291
QoL score 7.2±2.5 7.2±3.1 0.591
Total score 21.0±5.5 21.5±7.4 0.557
Values are presented as mean±standard deviation.
NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom In-
dex; QoL, quality of life.
Fig. 1. Evidence of chronic bacterial prostatitis in primary care 
clinic (n=77). The microbial pathogen distributions in a primary 
care clinic in Korea. The most common pathogen in primary 
care clinic was Enterococcus faecalis (19%), followed by Strepto-
coccus agalactiae (17%), Staphylococcus epidermidis (16%), 
Staphylococcus hemolyticus (8%), Staphylococcus aureus (8%), 



























Fig. 2. Evidence of chronic bacterial prostatitis in general hospi-
tal (n=12). The microbial pathogen distributions in a general 
hospital in Korea. The most common pathogen was Escherichia 
coli (41%), followed by Enterococcus faecalis (20%), Stwaphylo-
coccus epidermidis (13%), and Staphylococcus hemolyticus (13%).




talia (7%), and T. vaginalis (1%) (Fig. 3).
 The proportion of chronic bacterial prostatitis in the gen-
eral hospital was 46.6% (49/105), but in the PCC, it was 67.5% 
(127/188). The proportion of culture-positive chronic bacte-
rial prostatitis patients in the entire population sample was 
59.3%.
DISCUSSION
In the United States, prostatitis is diagnosed in 2,000,000 
visits annually, including 8% of all visits to urologists and 1% 
of all visits to primary care physicians [6]. Men with prosta-
titis symptoms appear to be at increased risk for persistent 
symptoms and recurrent episodes. Many studies have evalu-
ated the risk factors for recurrent prostatitis. Lifestyle, diet, 
smoking, gastrointestinal disease, anorectal disease, and 
even coitus seem to affect the prevalence of the disease [7-9]. 
However, we think that the risk factors for recurrent prostatitis 
are still controversial. In addition, over time, prostatitis-like 
symptoms result in a substantial number of physician visits. 
Nickel et al. [10] reported that 60% of patients with prostatitis-
like symptoms sought medical help. Moreover, patients with 
a previous diagnosis of prostatitis had a substantially higher 
cumulative probability of subsequent episodes [9,11].
 The treatment of the disease begins with its diagnosis. If the 
physician diagnoses the disease accurately, then the treatment 
can be applied immediately. However, in the chronic pros-
tatitis disease entity, the treatment might not be applicable. 
Because of diverse pathogens and pathogenesis [12,13], re-
currence is more common so the treatment period should be 
longer than in other diseases. Furthermore, in Korea, data on 
nation-wide prostatitis pathogens has not been available to 
physicians. The variability of pathogens in regional primary-
tertiary hospitals also remains unknown. Hence, the results 
of this study provide an important foundation for further re-
search, particularly comparisons between PCCs and tertiary 
general hospitals. 
 In our study, the results of the EPS culture showed signifi-
cant discrepancies between the PCC and the general hospital. 
The EPS culture-positive rate for the general hospital was only 
about 11%. However, in the PCC it about 40%. The PCC culture-
positive rate for EPS was higher than in other reports. de la Ro-
sette et al. [14] reported an EPS culture-positive rate of 10.4%, 
and Krieger et al. [15] reported an EPS culture-positive rate of 
7%. Because most microorganisms in the PCC were gram-pos-
itive, the potential reasons for the high culture-positive rate in 
the PCC could be skin contamination and inadequate sample 
acquisition. Furthermore, bias in the selection of the patients 
might account for the difference between these two medical 
institutions. To understand this result, we should understand 
the Korean healthcare system. 
 In Korea, the governmental referral system divides the 
medical institution into primary medical offices, secondary 
hospitals, and tertiary general hospitals. In this referral sys-
tem, it is recommended that patients visit their primary care 
physician first, but there is no restriction. Because the PCC 
is easy to access, patients can visit freely whenever they have 
symptoms. If symptoms persist after treatment in the PCC, 
then patients seek treatment in specialized hospital clin-
ics, followed by a tertiary general hospital [16]. Because the 
patients in the present sample first received treatment at the 
PCC, the culture-positive rate for the general hospital is lower 
than the PCC rate. However, according to the PCR analysis 
results, the number of patients showing positive PCR results 
almost equaled those in the PCC and the general hospital. 
Therefore, the results indicated that the chronic prostatitis 
pathogens in the PCC and the general hospital share a similar 
origin.
 The extraordinary finding in our study was the discrepancy 
in pathogens between the PCC and the general hospital. Un-
Fig. 3. Comparison of polymerase chain reaction (PCR) analyses 
of chronic bacterial prostatitis in primary care clinic (n=65) and 
general hospital (n=37). Comparison of the PCR analyses of 
chronic prostatitis in a general hospital and primary care clinic. 
The pathogenic distribution was different. The most common 
pathogen in the general hospital was C. trachomatis. In the pri-
mary care clinic, it was U. urealyticum.
General hospital
Primary care clinic






Table 2. Comparison of culture-positive patients in EPS and 
PCR culture in primary care clinic and general hospital 
Primary care clinic General hospital P-value
EPS/VB3 culture (+) 40.9 11.4 0.038
PCR (+) 34.5 35.2 0.275
EPS, expressed prostate secretion; PCR, polymerase chain reaction.




like the results of studies in western countries [15,17-19], PCR 
showed that the most common pathogen in the PCC was 
U. urealyticum. It accounted for 45% of all chronic bacterial 
prostatitis pathogens in the PCC. However, the results of the 
PCR showed that the most common pathogen in the general 
hospital was C. trachomatis, which accounted for 49% of all 
bacterial prostatitis pathogens. Because of the difference in 
the prevalence of pathogens, the treatment should differ ac-
cordingly. Although worldwide treatment guidelines are im-
portant [20,21], the disease entity might be different in each 
continent and each country. Therefore, the treatments should 
differ. The results of our Korean study showed that the most 
common chronic bacterial prostatitis pathogen in the PCC is 
Chlamydia, which and can be managed with azithromycin, 
doxycycline, or levofloxacin. In the general hospital, the most 
common pathogen in chronic bacterial prostatitis is Urea-
plasma, which also can be treated. The role of U. urealyticum 
in nonbacterial prostatitis is uncertain [22]. These microor-
ganisms are part of normal male urethral flora [23]. Therefore, 
the quantification of U. urealyticum is obligatory, thus allow-
ing comparison of the numbers of these microorganisms in 
EPS. Furthermore, in chronic bacterial prostatitis patients 
with clinical symptoms, U. urealyticum should be treated 
with doxycycline or tetracycline. Furthermore, because doxy-
cycline is not a primary treatment of choice for chronic bacte-
rial prostatitis, the physician should be aware of the patient’s 
symptoms and treatment history. 
 The PCR technique greatly affects the pathogenic diagnosis 
of bacterial prostatitis. Many patients have numerous previous 
courses of antibiotics, which could interfere with the cultivation 
of microorganisms. Many organisms seldom grow in most 
refined culture conditions. Although a higher proportion of 
cultivable microorganisms are known in humans, this source 
still contains a significant number of uncharacterized species 
that grow poorly on conventional media [24,25]. In spite of 
these shortcomings, the PCR technique does not need micro-
organisms to survive in laboratory conditions. Therefore, by 
using this technique, we can identify the causative organisms 
directly and rapidly.
 The limitation of this study is the relatively small popula-
tion sample. First, for epidemic evaluation, the enrollment of 
a greater number of patients is needed for analysis. The sec-
ond limitation is the bias in the selection of tertiary hospital 
patients. Because the patient population in general hospitals 
is clearly different from that in PCCs, the clinical impact of 
this study is limited. In spite of these shortcomings, this report 
compares the recent status of chronic bacterial prostatitis in 
PCCs and general hospitals. The results, especially the patho-
gen results, are unique. Compared with the results of studies 
in other countries, our results for chronic bacterial prostatitis 
are specific to conditions in Korean PCCs and general hospi-
tals.
 In conclusion, the proportion of patients that were culture-
positive for chronic bacterial prostatitis was significantly high-
er in the PCC than in the general hospital. However, the results 
of the PCR were the same for both the PCC and the general 
hospital. The proportion of patients in the entire population 
that were culture-positive for chronic bacterial prostatitis pa-
tients was 59.3%.
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